2. UroToday Home
  3. Video Lectures

Non-Muscle Invasive Bladder Cancer Videos

Pembrolizumab's Impact on Cystectomy-Free Survival in BCG Unresponsive Bladder Cancer from the KEYNOTE-057 Trial - Girish Kulkarni
May 19, 2023
Details
Managing Intermediate Risk Bladder Cancer: Treatment Strategies and Surveillance - Paolo Gontero & Gary Steinberg
May 19, 2023
Details
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
May 18, 2023
Details
TAR-200 in Combination with Cetrelimab for BCG Unresponsive Bladder Cancer (SunRISe-1) - Siamak Daneshmand
May 12, 2023
Details
Optimizing BCG Therapy in Bladder Cancer: Expert Insights on Managing Toxicity and Maximizing Efficacy - Badrinath Konety & Wassim Kassouf
May 12, 2023
Details
Debating Treatment Options for Very High-Risk Non-Muscle-Invasive Bladder Cancer: BCG vs. Radical Cystectomy - Morgan Rouprêt & Laura Mertens
May 12, 2023
Details
Gene Therapy and Pembrolizumab in BCG-Unresponsive CIS-Containing Population: Updated Results, Efficacy, and Correlative Studies - Roger Li
May 11, 2023
Details
En Bloc Resection vs. Standard Resection for Bladder Tumors: Multicenter Trial Results and Clinical Considerations - Jeremy Teoh
May 11, 2023
Details
Long-Term Survival Outcomes in Patients with BCG Unresponsive Non-Muscle Invasive Bladder Cancer: Evaluating Bladder-Sparing Treatment - Wei Shen Tan
May 11, 2023
Details
Assessing the Effectiveness of N-803 for BCG Unresponsive Bladder Cancer: Promising Complete Remission Rates and Improved Long-Term Response - Patrick Soon-Shiong
May 5, 2023
Details
Gemcitabine and Docetaxel Therapy Associated with Better Outcomes than BCG Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study - Vignesh Packiam
April 20, 2023
Details
The Importance of Proper Transurethral Resection of Bladder Tumors (TURBT) in Bladder Cancer Treatment - Arnulf Stenzl
April 10, 2023
Details
Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group: Intermediate-risk Non-muscle-invasive Bladder Cancer - Wei Shen Tan
March 14, 2023
Details
HIVEC-II Phase 2 Trial Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk NMIBC - Wei Shen Tan
March 14, 2023
Details
Results from Cohort B of the Phase 2 KEYNOTE-057 Trial, Pembrolizumab Monotherapy for Patients with High-Risk Non–muscle-Invasive Bladder Cancer Unresponsive to BCG - Andrea Necchi
March 16, 2023
Details
Clinical Perspective on Recurrence Mechanisms of Non-muscle Invasive Bladder Cancer – Jeremy Teoh
March 6, 2023
Details
The Clinical Benefits of Blue Light Cystoscopy in the Ambulatory Surgical Centers - Neal Shore
March 5, 2023
Details
Cell-Free Urinary DNA Predictive Impact on Patients with Non-Muscle Invasive Bladder Cancer - Kyle Rose
February 22, 2023
Details
The Explosion of Intravesical Therapy for Non-Muscle Invasive Bladder Cancer LUGPA 2022 Presentation - Colin Dinney
December 16, 2022
Details
Blue Light Powered by Saphira® for the Detection of Non Muscle-Invasive Bladder Cancer - Max Kates & Trinity J. Bivalacqua
November 16, 2022
Details
Non Muscle-Invasive Bladder Cancer: An Overview of Potential New Treatment Options - Beyond the Abstract
November 7, 2022
Details
Underlying Mechanism of Action of N-803 + BCG Inducing Durable Complete Response in BCG Unresponsive NMIBC -Patrick Soon-Shiong
October 27, 2022
Details
Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG the KEYNOTE-057 Study, Journal Club – Christopher Wallis & Zachary Klaassen
September 27, 2022
Details
BCG Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer - Seth Lerner
June 14, 2022
Details
Gene Therapy for Non-muscle Invasive Bladder Cancer - Roger Li
May 8, 2023
Details
Demonstrated Underuse of Blue Light Cystoscopy for Bladder Cancer in the United States - Patrick Lewicki
January 11, 2022
Details
The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz
October 1, 2021
Details
Novel Immune Checkpoint Axis To Understand BCG Resistance and Improve Treatment in Non-muscle Invasive Bladder Cancer - Amir Horowitz & John Sfakianos
May 10, 2021
Details
Conundrums in Bacillus Calmette Guerin (BCG) Unresponsive Nonmuscle Invasive Bladder Cancer Trials - Roger Li
May 8, 2021
Details
Combining BCG and Intravesical Gemcitabine (GBIG) for Patients with BCG-Relapsing High-Grade NMIBC Cancer A Phase 1/2 Trial- Eugene Pietzak
May 5, 2021
Details
The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker
May 5, 2021
Details
Improved Tumor Visibility, Detection Rate and Reduced Recurrence Rates After TURBT - Siamak Daneshmand and Marek Babjuk
April 21, 2021
Details
Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak
April 12, 2021
Details
Trained Immunity as a Molecular Mechanism for BCG Immunotherapy - Sita Vermeulen
January 27, 2021
Details
Nadofaragene Firadenovec for BCG Unresponsive NMIBC - Girish Kulkarni
January 5, 2021
Details
How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black
October 14, 2020
Details
High-Risk Non Muscle-Invasive BCG Unresponsive Bladder Cancer - Molecular Subtypes - Woonyoung Choi
October 14, 2020
Details
Adherence to Guidelines-Based Management of Non-Muscle Invasive Bladder Cancer Among Society of Urologic Oncology (SUO) Members - Justin T. Matulay
August 4, 2020
Details
Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney
July 6, 2020
Details
Phase III Nadofaragene Firadenovec for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Joshua J. Meeks
February 28, 2020
Details
Pembrolizumab in the BCG-unresponsive NMIBC Patients - Arjun Balar
February 22, 2020
Details